Skip to main content
2023 IKCS: Europe Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Video

Track: CME Session

SESSION 2: Understanding Renal Cell Carcinoma

Friday, April 21, 2023
10:15 – 11:30 GMT
Location: Lenox 3
CE: 1.25

    Moderator(s)

  • Samra Turajlic, PhD, MBBS, MRCP (she/her/hers)

    : Group Leader (Cancer Dynamics Laboratory, Francis Crick Institute) and Consultant Medical Oncologist (Royal Marsden NHS Foundation Trust)
    The Francis Crick Institute/ The Royal Marsden Hospital, United Kingdom

  • Elizabeth (Lisa) Henske, MD

    Physician, Principal Investigator
    Brigham and Women's Hospital, Harvard Medical School
    Brigham & Women's, Harvard Medical School

Presentations:

  • 10:16 – 10:17 GMT
    Introduction to Session 2

    Speaker: Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital

  • 10:17 – 10:27 GMT
    WHO pathological classification: Present and Future

    Speaker: Ferran Algaba Arrea, MD, PhD – Fundacio Puigvert. Universitat Autònoma de Barcelona-Spain

  • 10:27 – 10:37 GMT
    Artificial Intelligence and Digital Pathology- New tools in RCC for Diagnosis and Precision Oncology

    Speaker: Payal Kapur, MD (she/her/hers) – University of Texas Southwestern

  • 10:37 – 10:47 GMT
    Phase II study of nivolumab and salvage nivolumab + ipilimumab in RCC (HCRN GU16-260): Correlative Results

    Speaker: Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

  • 10:47 – 10:57 GMT
    Epigenetic regulation by PBRM1 in ccRCC

    Speaker: Jessica Downs, PhD (she/her/hers) – The Institute of Cancer Research

  • 10:57 – 11:07 GMT
    Non-Clear Cell RCC:  From Chromophobe to Translocation and Beyond

    Speaker: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School

  • 11:07 – 11:17 GMT
    Sarcomatoid and Rhadoid De-Differentiation in Renal Cell Carcinoma and Clinical Implications

    Speaker: Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic

  • 11:17 – 11:30 GMT
    Session 2 Q&A

    Moderator: Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital

    Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School